ArticleInternational journal of endocrinology2015

Beneficial Effects of the mTOR Inhibitor Everolimus in Patients with Advanced Medullary Thyroid Carcinoma: Subgroup Results of a Phase II Trial.

T C Schneider et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.